Last reviewed 2026-05-16 · How we verify

Joanne Kurtzberg, MD — Portfolio Competitive Intelligence Brief

Joanne Kurtzberg, MD pipeline: 0 marketed, 0 filed, 0 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

• Hematology · 1
• Immunology · 1
• Immunology, Regenerative Medicine · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

1. Biosolution Co., Ltd. · 1 shared drug class
2. Bone Therapeutics S.A · 1 shared drug class
3. Brainstorm-Cell Therapeutics · 1 shared drug class
4. Celavie Bioscences, LLC · 1 shared drug class
5. China Spinal Cord Injury Network · 1 shared drug class
6. City of Hope Medical Center · 1 shared drug class
7. DiscGenics, Inc. · 1 shared drug class
8. Avicenna Research Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Joanne Kurtzberg, MD:

• Joanne Kurtzberg, MD pipeline updates — RSS
• Joanne Kurtzberg, MD pipeline updates — Atom
• Joanne Kurtzberg, MD pipeline updates — JSON

Cite this brief

Drug Landscape (2026). Joanne Kurtzberg, MD — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/joanne-kurtzberg-md. Accessed 2026-05-16.

Related

• Joanne Kurtzberg, MD full company profile
• All CI briefs
• Build a custom feed